Laboratoires Expanscience
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 5 name spellings.
19
Ending by 2030
Nov 2026
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 28, 2027The maintenance fee for Medicament comprising a peptide extract of avocado, which is intended for the treatment and prevention of illnesses that are linked to an immune system deficiency or oxidative stress or skin ageing or dry skin (US 9,089,576) comes due Jan 28, 2027. Unpaid by Jul 28, 2027, it lapses early.
- 2 fees due Mar 8 to 15, 2027 · next Mar 8
- 3 fees due Apr 15 to 29, 2027 · next Apr 15
- 1 fee due May 5, 2027The maintenance fee for Lupin peptide extracts and skin firmness (US 10,463,593) comes due May 5, 2027. Unpaid by Nov 5, 2027, it lapses early.
- 1 fee due Aug 6, 2027The maintenance fee for Method for evaluating the effects of dehydration on children's skin (US 11,892,447) comes due Aug 6, 2027. Unpaid by Feb 7, 2028, it lapses early.
- 1 fee due Sep 15, 2027The maintenance fee for Composition including an unsaponifiable fraction (US 9,282,759) comes due Sep 15, 2027. Unpaid by Mar 15, 2028, it lapses early.
- 1 fee due Oct 14, 2027The maintenance fee for Surface isotropy as a marker for epidermal maturation (US 10,620,189) comes due Oct 14, 2027. Unpaid by Apr 14, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,863,472 | Process for Producing Refined Avocado Oil Rich in Triglycerides, and Oil Obtainable by Said Process In force · High confidence | In force | High confidence | |
| US 7,833,554 | Medicament comprising a peptide extract of avocado, which is intended for the treatment and prevention of illnesses that are linked to an immune system deficiency In force · From the USPTO record | In force | From the USPTO record | |
| US 8,734,865 | Lupin total extract consisting of a lupin sugar extract and a lupin peptide extract, method for the production and use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 9,089,576 | Medicament comprising a peptide extract of avocado, which is intended for the treatment and prevention of illnesses that are linked to an immune system deficiency or oxidative stress or skin ageing or dry skin In force · From the USPTO record | In force | From the USPTO record | |
| US 9,023,810 | Use of a Compound Comprising D-Mannoheptulose And/Or Perseitol for Treating and Preventing Innate Immunity Modification Diseases In force · Low confidence | In force | Low confidence | |
| US 8,304,453 | Composition comprising at least one alkanolamide to inhibit migration of langerhans cells and uses therof In force · From the USPTO record | In force | From the USPTO record | |
| US 8,231,916 | Use of a rice protein hydrolysate as pigmenting active principle In force · From the USPTO record | In force | From the USPTO record | |
| US 8,747,815 | Use of a cosmetic of pharmaceutical composition, comprising a lupeol-rich extract as an active ingredient for stimulating the synthesis of heat shock proteins In force · From the USPTO record | In force | From the USPTO record | |
| US 8,859,617 | Use of furan alkyl for preparing an antidiabetic drug In force · From the USPTO record | In force | From the USPTO record | |
| US 7,816,547 | Process for Producing Refined Avocado Oil Rich in Triglycerides, and Oil Obtainable by Said Process In force · High confidence | In force | High confidence |
Also on record, not counted in the 52: 1 patent in force now held by others · 4 lapsed for an unpaid fee · 24 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending · 2 abandoned · 13 no status recorded